Blueteq News
NCPE — First National HTA Using EU Joint Clinical Assessment Data
The NCPE completed a rapid review of onasemnogene abeparvovec intrathecal (Itvisma®), Novartis’s intrathecal gene therapy for spinal muscular atrophy (SMA), making this the first national
UK–US Arrangement – Jersey & Guernsey
The UK–US Trade Agreement and the NICE threshold changes do not apply in Jersey or Guernsey, which are not part of the NHS and operate
UK–US Arrangement — Relevance to Northern Ireland
The VPAG rebate is negotiated on behalf of all four UK nations. The reduction of the VPAG rebate from 22.9% to 14.5% therefore applies to
UK–US Arrangement — Relevance to Wales
The NICE threshold increase from April 2026 applies to NHS Wales, which follows NICE technology appraisals automatically. Nine additional medicines approved under the new threshold
SMC Decisions — 13 July 2026
SMC Decisions — 13 July 2026 The Scottish Medicines Consortium published advice on six medicines on 13 July 2026. Five, which appear to be high
UK–US Trade Agreement and July Developments
UK–US Trade Agreement and July Developments On 2 July 2026, the Department of Health announced a series of fast-track drug access pilots from September 2026. 1
